<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    9732338
   </pmid>
   <datecreated>
    <year>
     1998
    </year>
    <month>
     10
    </month>
    <day>
     28
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1998
    </year>
    <month>
     10
    </month>
    <day>
     28
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2009
    </year>
    <month>
     11
    </month>
    <day>
     18
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0959-8138
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       317
      </volume>
      <issue>
       7160
      </issue>
      <pubdate>
       <year>
        1998
       </year>
       <month>
        Sep
       </month>
       <day>
        12
       </day>
      </pubdate>
     </journalissue>
     <title>
      BMJ (Clinical research ed.)
     </title>
     <isoabbreviation>
      BMJ
     </isoabbreviation>
    </journal>
    <articletitle>
     Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.
    </articletitle>
    <pagination>
     <medlinepgn>
      713-20
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To determine whether tight control of blood pressure with either a beta blocker or an angiotensin converting enzyme inhibitor has a specific advantage or disadvantage in preventing the macrovascular and microvascular complications of type 2 diabetes.
     </abstracttext>
     <abstracttext label="DESIGN" nlmcategory="METHODS">
      Randomised controlled trial comparing an angiotensin converting enzyme inhibitor (captopril) with a beta blocker (atenolol) in patients with type 2 diabetes aiming at a blood pressure of &lt;150/&lt;85 mm Hg.
     </abstracttext>
     <abstracttext label="SETTING" nlmcategory="METHODS">
      20 hospital based clinics in England, Scotland, and Northern Ireland.
     </abstracttext>
     <abstracttext label="SUBJECTS" nlmcategory="METHODS">
      1148 hypertensive patients with type 2 diabetes (mean age 56 years, mean blood pressure 160/94 mm Hg). Of the 758 patients allocated to tight control of blood pressure, 400 were allocated to captopril and 358 to atenolol. 390 patients were allocated to less tight control of blood pressure.
     </abstracttext>
     <abstracttext label="MAIN OUTCOME MEASURES" nlmcategory="METHODS">
      Predefined clinical end points, fatal and non-fatal, related to diabetes, death related to diabetes, and all cause mortality. Surrogate measures of microvascular and macrovascular disease included urinary albumin excretion and retinopathy assessed by retinal photography.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      Captopril and atenolol were equally effective in reducing blood pressure to a mean of 144/83 mm Hg and 143/81 mm Hg respectively, with a similar proportion of patients (27% and 31%) requiring three or more antihypertensive treatments. More patients in the captopril group than the atenolol group took the allocated treatment: at their last clinic visit, 78% of those allocated captopril and 65% of those allocated atenolol were taking the drug (P&lt;0.0001). Captopril and atenolol were equally effective in reducing the risk of macrovascular end points. Similar proportions of patients in the two groups showed deterioration in retinopathy by two grades after nine years (31% in the captopril group and 37% in the atenolol group) and developed clinical grade albuminuria &gt;=300 mg/l (5% and 9%). The proportion of patients with hypoglycaemic attacks was not different between groups, but mean weight gain in the atenolol group was greater (3.4 kg v 1.6 kg).
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      Blood pressure lowering with captopril or atenolol was similarly effective in reducing the incidence of diabetic complications. This study provided no evidence that either drug has any specific beneficial or deleterious effect, suggesting that blood pressure reduction in itself may be more important than the treatment used.
     </abstracttext>
    </abstract>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Comparative Study
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
     <publicationtype>
      Research Support, U.S. Gov't, P.H.S.
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     ENGLAND
    </country>
    <medlineta>
     BMJ
    </medlineta>
    <nlmuniqueid>
     8900488
    </nlmuniqueid>
    <issnlinking>
     0959-535X
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Adrenergic beta-Antagonists
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Angiotensin-Converting Enzyme Inhibitors
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Antihypertensive Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Hemoglobin A, Glycosylated
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      29122-68-7
     </registrynumber>
     <nameofsubstance>
      Atenolol
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      62571-86-2
     </registrynumber>
     <nameofsubstance>
      Captopril
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="Cites">
     <refsource>
      Diabet Med. 1994 Oct;11(8):773-82
     </refsource>
     <pmid version="1">
      7851072
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      BMJ. 1998 Sep 12;317(7160):703-13
     </refsource>
     <pmid version="1">
      9732337
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1998 Jul 18;352(9123):213-9
     </refsource>
     <pmid version="1">
      9683226
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      BMJ. 1998 Jun 27;316(7149):1921
     </refsource>
     <pmid version="1">
      9641925
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Diabetologia. 1998 May;41(5):598-602
     </refsource>
     <pmid version="1">
      9628280
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      BMJ. 1992 Oct 24;305(6860):981-5
     </refsource>
     <pmid version="1">
      1458144
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1990 Apr 7;335(8693):827-38
     </refsource>
     <pmid version="1">
      1969567
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Intern Med. 1991 Jun;229(6):489-92
     </refsource>
     <pmid version="1">
      2045754
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      BMJ. 1988 Oct 29;297(6656):1092-5
     </refsource>
     <pmid version="1">
      2848604
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71
     </refsource>
     <pmid version="1">
      2858114
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Diabetes Care. 1987 Mar-Apr;10(2):200-4
     </refsource>
     <pmid version="1">
      3034532
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Am J Med. 1995 Nov;99(5):497-504
     </refsource>
     <pmid version="1">
      7485207
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      JAMA. 1995 May 10;273(18):1450-6
     </refsource>
     <pmid version="1">
      7654275
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Br Med Bull. 1994 Apr;50(2):272-98
     </refsource>
     <pmid version="1">
      8205459
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      N Engl J Med. 1993 Nov 11;329(20):1456-62
     </refsource>
     <pmid version="1">
      8413456
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Ann Intern Med. 1993 Jan 15;118(2):129-38
     </refsource>
     <pmid version="1">
      8416309
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Circulation. 1996 Aug 15;94(4):673-82
     </refsource>
     <pmid version="1">
      8772687
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      JAMA. 1996 Dec 18;276(23):1886-92
     </refsource>
     <pmid version="1">
      8968014
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Am Coll Cardiol. 1997 Jul;30(1):27-34
     </refsource>
     <pmid version="1">
      9207617
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1997 Jun 21;349(9068):1787-92
     </refsource>
     <pmid version="1">
      9269212
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 1999 Mar 6;318(7184):667-8
     </refsource>
     <pmid version="1">
      10215366
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 1999 Mar 6;318(7184):667; author reply 668
     </refsource>
     <pmid version="1">
      10215364
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 1999 Mar 6;318(7184):666-7; author reply 668
     </refsource>
     <pmid version="1">
      10066218
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 1998 Sep 12;317(7160):693-4
     </refsource>
     <pmid version="1">
      9732334
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 1998 Sep 12;317(7160):691-2
     </refsource>
     <pmid version="1">
      9732333
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adrenergic beta-Antagonists
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Angiotensin-Converting Enzyme Inhibitors
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Antihypertensive Agents
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Atenolol
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Captopril
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Cerebrovascular Disorders
     </descriptorname>
     <qualifiername majortopicyn="N">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Diabetes Mellitus, Type 2
     </descriptorname>
     <qualifiername majortopicyn="Y">
      complications
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Diabetic Angiopathies
     </descriptorname>
     <qualifiername majortopicyn="N">
      physiopathology
     </qualifiername>
     <qualifiername majortopicyn="Y">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Diabetic Retinopathy
     </descriptorname>
     <qualifiername majortopicyn="N">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Follow-Up Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hemoglobin A, Glycosylated
     </descriptorname>
     <qualifiername majortopicyn="N">
      metabolism
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hypertension
     </descriptorname>
     <qualifiername majortopicyn="Y">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hypoglycemia
     </descriptorname>
     <qualifiername majortopicyn="N">
      chemically induced
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Myocardial Infarction
     </descriptorname>
     <qualifiername majortopicyn="N">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Patient Compliance
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Peripheral Vascular Diseases
     </descriptorname>
     <qualifiername majortopicyn="N">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Prospective Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Treatment Outcome
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Visual Acuity
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Weight Gain
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug effects
     </qualifiername>
    </meshheading>
   </meshheadinglist>
   <otherid source="NLM">
    PMC28660
   </otherid>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1998
     </year>
     <month>
      9
     </month>
     <day>
      11
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1998
     </year>
     <month>
      9
     </month>
     <day>
      11
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1998
     </year>
     <month>
      9
     </month>
     <day>
      11
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     9732338
    </articleid>
    <articleid idtype="pmc">
     PMC28660
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

